atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
atai Life Sciences (NASDAQ: ATAI) has appointed Scott Braunstein, M.D., and Laurent Fischer, M.D., as new independent directors to its supervisory board, effective May 23, 2024. Scott Braunstein is the CEO and Chairman of Marinus Pharmaceuticals and has held key positions at Pacira Pharmaceuticals and JP Morgan Global Healthcare Fund. Laurent Fischer currently serves as the CEO and President of Adverum Biotechnologies and has a robust background with roles at CTI Biopharma, Tobira Therapeutics, and others. Jason Camm steps down after four years of service. The addition of Braunstein and Fischer is expected to strengthen atai's board as the company progresses into advanced clinical trials.
- Appointment of two experienced biopharmaceutical executives to the board.
- Scott Braunstein's extensive experience in managing pharmaceutical companies and healthcare funds.
- Laurent Fischer's leadership roles in multiple biopharmaceutical companies and extensive industry experience.
- Both new directors have a strong background in drug development and commercialization, which could be beneficial for atai’s strategic objectives.
- Resignation of Jason Camm, who had been with the board for four years, might indicate internal changes or instability.
- Potential delays or disruptions during the transition period as new board members integrate.
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements.
Scott Braunstein, M.D., is the Chief Executive Officer (“CEO”) and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operating Officer at Pacira Pharmaceuticals, Inc. and portfolio manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group, earning his medical degree from the Albert Einstein College of Medicine and his undergraduate degree from Cornell University.
Laurent Fischer, M.D., is the CEO and President of Adverum Biotechnologies and serves on the Board of Directors at Mirum Pharmaceuticals, Inc., Lycia Therapeutics and Teal. Previously, Dr. Fischer was Chairman of CTI Biopharma, CEO of Tobira Therapeutics (subsequently Allergan), and held leadership roles at Jennerex, RXCentric (now part of Allscripts Healthcare Solutions), MedVantx, Dupont Pharmaceuticals, Dupont-Merck, and F. Hoffmann-La Roche. Dr. Fischer earned an undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.
Further, the Company announced that after four years of service, Jason Camm has stepped down from the Board.
Christian Angermayer, Founder and Chairman of atai, said: “I am thrilled to welcome Scott and Laurent to atai’s Board. Their remarkable achievements in the biopharmaceutical sector and comprehensive understanding of drug development and commercialization will be instrumental to our Board and management team as we advance into later-stage clinical trials. I also want to thank Jason for his invaluable contributions over the past few years.”
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: expectations regarding our supervisory board; our business strategy and plans; and the plans and objectives of management for future operations and capital expenditures.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Contact Information
Investor Contact:
Media Contact:
FAQ
Who are the new independent directors appointed to atai Life Sciences' board?
When were the new directors Scott Braunstein and Laurent Fischer appointed to atai Life Sciences?
What is Scott Braunstein's professional background?
What is Laurent Fischer’s professional background?
Why is Jason Camm stepping down from atai Life Sciences' board?
How might the new appointments impact atai Life Sciences' future?
